Recent Updates
Recently added Catalysts

Triage Profiler S.O.B. Panel

Phase 2

Acute Myocardial Infarction | Unknown | Cardiovascular |Abbott Laboratories|Last Updated: Jul 27, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindNO_TREATMENT_CONTROLLEDBiomarker
Total Trials1
Total Enrollment306
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00206830SHORTness of Breath In the Emergency Department (SHORTIE)PHASE2 COMPLETED 306Apr 1, 2005Aug 1, 2007Jul 27, 20155 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Time to specific treatment for final diagnosis
Length of stay in the emergency department (ED)
ED and total hospital costs
Secondary Endpoints
Outcome at 30 days (Phase I and II) and 90 days (Phase II)
Diagnostic accuracy of the Triage® Profiler S.O.B. panel for acute myocardial infarction (AMI), heart failure (HF) and pulmonary embolism (PE) in patients presenting with S.O.B.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
Control-Blinded from ResultsNO_INTERVENTION -
Access to ResultsEXPERIMENTAL -
Interventions
NameTypeDescription
Triage Profiler S.O.B. PanelDEVICE -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Age 18 and older. * Visit to the ED is due to a primary complaint of shortness of breath alone or shortness of breath with associated chest pain, cough or edema. Exclusion Criteria: * Blood sample cannot be collected before treatment is initiated, specifically CPR or treatme...

Countries:United States
Unlock Eligibility Criteria